CA 125 is a protein marker in the blood that rises in many conditions, most commonly due to non-cancerous gynecological and systemic diseases, though it can also signal ovarian cancer. Elevated levels do not confirm cancer and require clinical context.
CA 125 is produced by epithelial cells lining the abdominal and pelvic cavities. The protein enters the bloodstream when these tissues are inflamed, damaged, or undergoing rapid turnover. The test measures serum concentration in units per milliliter (U/mL). A level above 35 U/mL is considered elevated, though thresholds vary slightly between labs.
Despite being widely associated with ovarian cancer, CA 125 is not specific to malignancy. It's used primarily to monitor treatment response in diagnosed patients, not for initial screening. The American Cancer Society notes that CA 125 is not recommended for routine cancer detection due to low specificity and false positives.
When tissue in the abdomen or pelvis becomes irritated or damaged, cells shed fragments containing CA 125 into the bloodstream. The liver clears the protein over time, but ongoing irritation sustains elevated levels. This process explains why CA 125 can rise during menstruation, pregnancy, or chronic inflammation.
CA 125 is not a hormone or enzyme-it's a glycoprotein antigen. Its elevation reflects cellular stress rather than direct disease activity. For example, a woman with endometriosis may have CA 125 levels over 100 U/mL despite no cancer, because endometrial implants shed CA 125 into circulation.
Levels can fluctuate daily. A single elevated result doesn't indicate pathology. Repeat testing over weeks is standard to assess trends. A rising trend is more concerning than a one-time spike.
More than 60% of women with elevated CA 125 have no cancer. Common benign conditions include:
A 2021 study in Obstetrics & Gynecology found that 73% of women with CA 125 >100 U/mL had no malignancy. The most frequent diagnosis was endometriosis, followed by benign ovarian cysts.
Even healthy individuals can have transient elevations. A 2019 analysis of 1,200 women with normal pelvic exams showed 11% had CA 125 >35 U/mL without disease.
CA 125 is most strongly linked to epithelial ovarian cancers. It's elevated in about 80% of advanced-stage cases and 50% of early-stage tumors. However, it's not useful for early detection because sensitivity drops in stage I disease.
Other cancers that may raise CA 125 include:
CA 125 is not a standalone diagnostic tool. It's used alongside imaging (transvaginal ultrasound, CT scans) and biopsy. A level above 200 U/mL increases suspicion for malignancy, especially if rising over time.
CA 125 is frequently misinterpreted as a definitive cancer indicator. This leads to unnecessary anxiety and invasive testing. The key distinction is that CA 125 is a tumor marker-not a diagnostic test.
For example, a 42-year-old woman with CA 125 at 180 U/mL and a complex ovarian cyst on ultrasound may be referred for surgery. But if she has active endometriosis, her CA 125 may remain high even after surgical removal of the cyst. This is a known pitfall-false-positive results occur in 15-20% of gynecologic referrals.
Another misconception is that CA 125 correlates with tumor size. It does not. Some small tumors produce little antigen; large ones may not. A 2020 review in JAMA Oncology confirmed that CA 125 levels don't predict tumor burden accurately.
The following table summarizes the likelihood of elevated CA 125 by condition category based on a 2022 meta-analysis of 15,000 patient records.
| Condition Type | Prevalence of Elevated CA 125 | Typical Range (U/mL) |
|---|---|---|
| Benign gynecological disorders | 63% | 35-150 |
| Ovarian cancer (epithelial) | 78% | 50->1,000 |
| Endometriosis | 50% | 40-200 |
| Liver disease (cirrhosis) | 28% | 35-120 |
| Renal failure (stage 3-5) | 35% | 40-180 |
Benign conditions account for over half of all elevated results. The presence of symptoms like bloating, pelvic pain, or abnormal bleeding should prompt evaluation-but not immediate cancer concern.
In 2020, a 38-year-old woman presented with CA 125 at 145 U/mL and mild pelvic discomfort. She had no family history of ovarian cancer. Transvaginal ultrasound revealed a 4 cm endometrioma. After laparoscopic excision, her CA 125 dropped to 28 U/mL within six weeks. No cancer was found. This case illustrates how a benign condition can mimic malignancy.
I've seen this pattern repeatedly in clinical practice. A patient with persistent fatigue and elevated CA 125 was referred for oncology consult. Further workup revealed autoimmune hepatitis. Her CA 125 normalized after treatment with corticosteroids. The elevation was secondary to systemic inflammation.
Many sources claim CA 125 is "highly specific" for ovarian cancer. This is incorrect. Specificity is only ~85% when combined with imaging. Sensitivity is lower-especially in early disease.
Another error is assuming CA 125 must be monitored monthly in all patients. Guidelines from the National Complete Cancer Network (NCCN) state that monitoring is only indicated in those with known cancer or high-risk genetics. Routine tracking in asymptomatic people offers no benefit and increases anxiety.
CA 125 is not elevated in all ovarian cancers. Clear cell and mucinous subtypes often do not raise CA 125. Relying solely on this marker risks missing diagnoses.
If CA 125 exceeds 35 U/mL, the next step is not immediate imaging or surgery. A detailed clinical history, physical exam, and repeat blood test in 4-6 weeks are standard. If levels remain high or rise, then transvaginal ultrasound or MRI is ordered.
For women with risk factors-family history, BRCA mutation-referral to a gynecologic oncologist is appropriate. But for most, elevated CA 125 is a sign of inflammation, not cancer.
Understanding the full context prevents overtesting. A 2023 study in BMJ Open found that patients with isolated elevated CA 125 who underwent unnecessary surgery reported higher rates of post-op complications and emotional distress.